Market Overview:

The global hydrocephalus shunts market reached a value of US$ 412.6 Million in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 540.4 Million by 2027 exhibiting a CAGR of 4.20% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Hydrocephalus shunts refer to a medical device used for treating a condition that occurs when fluid builds up in the brain and results in increased intracranial pressure within the skull. It is commonly available in valves, catheters, adjustable pressure valves and fixed pressure valve variants. It is a flexible tube placed into the brain area where cerebrospinal fluid (CSF) is produced. Hydrocephalus shunts consist of an inflow or proximal catheter that drains CSF from the lateral ventricles, a valve mechanism that regulates intracranial pressure by controlling fluid flow and an outflow or distal catheter that runs under the skin and directs CSF. It assists in soothing the tension on the cerebrum and returning the brain's enlarged ventricles to their actual size.

Hydrocephalus Shunts Market Trends:

The increasing prevalence of brain and neurological disorders among the masses is one of the key factors driving the growth of the market. Hydrocephalus shunts are widely used due to the rising incidence of congenital abnormalities, brain and nerve injuries, accidents leading to central nervous system (CNS) defects and lifestyle diseases. Additionally, the increasing product demand to treat hydrocephalus among infants that could lead to enlargement of the head and damaging brain is favoring the market growth. Moreover, various technological advancements, such as the development of anti-siphon devices that assist in avoiding siphon effects over cerebrospinal fluid, are providing a thrust to the market growth. In line with this, the development of programmable valves for controlling the flow of cerebrospinal fluid and preventing it from moving in the wrong direction is positively impacting the market growth. Other factors, including significant growth in the healthcare industry, along with the implementation of various government initiatives to spread awareness regarding hydrocephalus shunts, are anticipated to drive the market toward growth further across the globe.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global hydrocephalus shunts market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, product type, age group and end user.

Breakup by Type:

• Ventriculo-Peritoneal
• Ventriculo-Atrial
• Ventriculo-Pleural
• Lumbo-Peritoneal
   

Breakup by Product Type:

• Hydrocephalus Valves
  • Adjustable Pressure Valves
  • Fix Pressure Valves
• Hydrocephalus Catheters
   

Breakup by Age Group:

• Infants
• Children
• Adults
   

Breakup by End User:

• Hospitals
• Ambulatory Surgical Centers
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Argi Group, B. Braun Melsungen AG, Christoph Miethke GmbH & Co. KG, G. Surgiwear Ltd., HLL Lifecare Limited, Integra LifeSciences, Kaneka Medix Corporation (Kaneka Corporation), Medtronic Plc, Natus Medical Incorporated, Sophysa, Spiegelberg GmbH & Co. KG (SHS Medizintechnik Holding GmbH) and TKB Corporation.

Report Coverage: